Evidence map›Paper›PMID 26599443›Full record

ArticleScientific reports2015

Composition and Interactions of Hepatitis B Virus Quasispecies Defined the Virological Response During Telbivudine Therapy.

Bin Zhou, Hui Dong, Yungang He, Jian Sun, Weirong Jin, Qing Xie, Rong Fan, Minxian Wang, Ran Li, Yangyi Chen and 11 more

Abstract read
In one paragraph

Article in Scientific reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Bin ZhouState Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Hui DongShanghai-MOST Key Laboratory of Health and Disease Genomics, Chinese National Human Genome Center at Shanghai, Shanghai, China.
Yungang HeCAS Key Laboratory of Computational Biology, CAS-MPG Partner Institute for Computational Biology; CAS Key Laboratory of Synthetic Biology, Institute of Plant Physiology and Ecology; Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, China.
Jian SunState Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Weirong JinShanghai-MOST Key Laboratory of Health and Disease Genomics, Chinese National Human Genome Center at Shanghai, Shanghai, China.
Qing XieDepartment of Infectious Diseases, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Rong FanState Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Minxian WangCAS Key Laboratory of Computational Biology, CAS-MPG Partner Institute for Computational Biology; CAS Key Laboratory of Synthetic Biology, Institute of Plant Physiology and Ecology; Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, China.
Ran LiCAS Key Laboratory of Computational Biology, CAS-MPG Partner Institute for Computational Biology; CAS Key Laboratory of Synthetic Biology, Institute of Plant Physiology and Ecology; Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, China.
Yangyi ChenShanghai-MOST Key Laboratory of Health and Disease Genomics, Chinese National Human Genome Center at Shanghai, Shanghai, China.
Shaoqing XieShanghai Shenyou Biotechnology Co., Ltd., Shanghai, China.
Yan ShenShanghai Shenyou Biotechnology Co., Ltd., Shanghai, China.
Xin HuangCAS Key Laboratory of Computational Biology, CAS-MPG Partner Institute for Computational Biology; CAS Key Laboratory of Synthetic Biology, Institute of Plant Physiology and Ecology; Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, China.
Shengyue WangShanghai-MOST Key Laboratory of Health and Disease Genomics, Chinese National Human Genome Center at Shanghai, Shanghai, China.
Fengming LuDepartment of Microbiology and Infectious Disease Center, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China.
Jidong JiaLiver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Hui ZhuangDepartment of Microbiology and Infectious Disease Center, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China.
Stephen LocarniniVictorian Infectious Diseases Reference Laboratory, North Melbourne, Victoria, Australia.
Guo-Ping ZhaoShanghai-MOST Key Laboratory of Health and Disease Genomics, Chinese National Human Genome Center at Shanghai, Shanghai, China.
Li JinCAS Key Laboratory of Computational Biology, CAS-MPG Partner Institute for Computational Biology; CAS Key Laboratory of Synthetic Biology, Institute of Plant Physiology and Ecology; Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, China.
Jinlin HouState Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Reverse transcriptase (RT) mutations contribute to hepatitis B virus resistance during antiviral therapy with nucleos(t)ide analogs. However, the composition of the RT quasispecies and their interactions during antiviral treatment have not yet been thoroughly defined. In this report, 10 patients from each of 3 different virological response groups, i.e., complete virological response, partial virological response and virological breakthrough, were selected from a multicenter trial of Telbivudine treatment. Variations in the drug resistance-related critical RT regions in 107 serial serum samples from the 30 patients were examined by ultra-deep sequencing. A total of 496,577 sequence reads were obtained, with an average sequencing coverage of 4,641X per sample. The phylogenies of the quasispecies revealed the independent origins of two critical quasispecies, i.e., the rtA181T and rtM204I mutants. Data analyses and theoretical modeling showed a cooperative-competitive interplay among the quasispecies. In particular, rtM204I mutants compete against other quasispecies, which eventually leads to virological breakthrough. However, in the absence of rtM204I mutants, synergistic growth of the drug-resistant rtA181T mutants with the wild-type quasispecies could drive the composition of the viral population into a state of partial virological response. Furthermore, we demonstrated that the frequency of drug-resistant mutations in the early phase of treatment is important for predicting the virological response to antiviral therapy.

Indexed as

AdultAntiviral AgentsDNA, ViralDrug Resistance, ViralFemaleHepatitis B, ChronicHepatitis B Surface AntigensHepatitis B virusHigh-Throughput Nucleotide SequencingHumansMaleMiddle AgedMutationPhylogenyRemission InductionRNA-Directed DNA PolymeraseAntiviral AgentsDNA, ViralHepatitis B Surface AntigensRNA-Directed DNA PolymeraseTelbivudineThymidine

Identifiers

PMID26599443
PMCPMC4657086

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.